526
Participants
Start Date
January 31, 2007
Primary Completion Date
January 31, 2013
Study Completion Date
January 31, 2013
ABR-217620/naptumomab estafenatox
10 mcg/kg or 15 mcg/kg, 5 minute bolus intravenous injection on 4 consecutive days / 8 week cycle repeated 3 times
IFN-alpha
3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
"Multifile Hospital Aleksandrovska, Urology Clinic, Department of Oncourology", Sofia
"Oncology Clinic, University General Hospital for Active Treatment Tzaritza Yoanna", Sofia
1st Internal Department District Dispensary for Cancer Diseases with Inpatient Hospital, Plovdiv
Department of Chemotherapy, Inter-district Dispensary for Cancer Diseases with Inpatient Hospital, Veliko Tarnovo
"Department of Chemotherapy, University General Hospital for Active Treatment Georgi Stranski", Pleven
"Urology Clinic, General Hospital for Active Treatment St. Anna", Varna
Chernigov Regional Oncology Center, Chernihiv
Cherkassy Regional Oncology Center, Cherkassy
Urology Department, Dnepropetrovsk State Medical Academy, Dnipro
City General Hospital #4, Dnipro
Kharkiv Regional Urology and Nephrology Center, Kharkiv
Ivano-Frankovsk Regional Oncology Center, Ivano-Frankivsk
State Regional Diagnostics and Treatment Oncology Center, Lviv
Donetsk Regional Antitumor Center, Donetsk
Regional Oncology Center, Uzhhorod
Research Institute of Urology, Moscow
Russian Oncological Research Center n.a. N.N. Blokhin, Moscow
Russian Research Center of Radiology, Moscow
Regional Clinical Oncology Hospital, Yaroslavl
Leningrad Regional Oncological Center, Saint Petersburg
Municipal Aleksandrovskaya Hospital, Saint Petersburg
Municipal Multi-Speciality Hospital #2, Saint Petersburg
Municipal Hospital #26, Saint Petersburg
Municipal Clinical Oncology Center, Saint Petersburg
Central Research Institute of Roentgenology and Radiology, Saint Petersburg
Research Institute of Oncology n.a. Professor N.N. Petrov, Saint Petersburg
Municipal Hospital #15, Saint Petersburg
Medical Radiology Research Center, Obninsk
Oncomed SRL, Timișoara
Stavropol Territorial Clinical Oncology Center, Stavropol
"I. Chiricuta Institute of Oncology", Cluj-Napoca
E-URO Medical Center, Cluj-Napoca
Republican Clinical Oncology Center, Kazan'
Kazan City Oncology Center, Kazan'
Chelyabinsk Regional Oncology Center, Chelyabinsk
Orenburg Regional Clinical Oncology Center, Orenburg
Sibiu Clinical Country Hospital - Urology Clinic, Sibiu
Provita Center SRL, Constanța
Fundeni Clinical Institute - Urology Department, Bucharest
Dinu Uromedica, Bucharest
"Prof. Dr. Th. Burghele Clinical Hospital, Urology Clinic", Bucharest
Arkhangelsk Regional Oncology Center, Arkhangelsk
Institute of Urology under the Academy of Medical Sciences of Ukraine, Department of Plastic and Supportive Urology, Kiev
Institute of Urology under the Academy of Medical Sciences of Ukraine, Urology Department, Kiev
Addenbrooke's Hospital, Cambridge Clinical Trials Centre, Cambridge
Derby Hospital NHS Trust, Derby
The Beatson West of Scotland Cancer Centre, Glasgow
St. James's Institute of Oncology, Leeds
The Royal Marsden NHS Trust, London
The Christie Hospital NHS Trust, Manchester
South Wales Cancer Institute, Singleton Hospital, Swansea
Lead Sponsor
Active Biotech AB
INDUSTRY